Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tranexamic acid in spinal surgery: a stratified protocol from the surgeon's point of view.

Brain & spine·2026
Same author

A standard operating procedure for reducing risk from medications prohibited during clinical trials in cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

Retrospective analysis of the incidence and clinicopathological findings associated with ammonium urate urolithiasis in dogs with congenital portosystemic shunts: 363 cases (2010-2023).

The Journal of small animal practice·2025
Same author

Bessel's disease-the first report of an IgG4-related disorder.

Zeitschrift fur Rheumatologie·2024
Same author

Neutrophils seeking new neighbors: radiotherapy affects the cellular framework and the spatial organization in a murine breast cancer model.

Cancer immunology, immunotherapy : CII·2024
Same author

["Rheuma (be-)greifen"- A multimodal teaching concept to improve rheumatology education for medical students].

Zeitschrift fur Rheumatologie·2023
Same journal

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same journal

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Annals of the rheumatic diseases·2026
Same journal

PD-1 signalling restrains pathogenic T peripheral helper and effector CD4⁺ T cell functions in rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same journal

Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.

Annals of the rheumatic diseases·2026
Same journal

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same journal

Commentary on 'Assessing the performance of AI chatbots in answering patients common questions about low back pain'.

Annals of the rheumatic diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

Interleukin-1 is essential for systemic inflammatory bone loss.

K Polzer1, L Joosten, J Gasser

  • 1Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen, 91054 Erlangen, Germany.

Annals of the Rheumatic Diseases
|February 7, 2009
PubMed
Summary
This summary is machine-generated.

Interleukin-1 (IL1) is essential for tumour necrosis factor (TNF)-induced bone loss. Blocking IL1 fully protects against TNF-mediated bone loss, even with joint inflammation, highlighting IL1's role in inflammatory osteopenia.

Related Experiment Videos

Last Updated: Jun 25, 2026

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
06:29

Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay

Published on: March 1, 2011

Area of Science:

  • Immunology
  • Bone Biology
  • Rheumatology

Background:

  • Chronic inflammation is a key driver of systemic bone loss and osteoporotic fractures.
  • Tumour necrosis factor (TNF) and interleukin-1 (IL1) are implicated in inflammation-induced bone loss, but their specific roles require clarification.

Purpose of the Study:

  • To investigate whether TNF directly causes bone loss or if IL1 is a necessary mediator.
  • To elucidate the role of IL1 in TNF-driven bone resorption and inflammatory osteopenia.

Main Methods:

  • Human TNFalpha transgenic (hTNFtg) mice were crossed with IL1-deficient mice (IL1(-/-)hTNFtg).
  • Systemic bone architecture was assessed using CT scanning, histomorphometry, and serum bone metabolism markers.
  • Osteoclast and osteoblast activity, along with RANKL levels, were analyzed.

Main Results:

  • hTNFtg mice exhibited severe bone loss and microarchitectural deterioration, with increased bone resorption and RANKL.
  • IL1(-/-)hTNFtg mice were protected from bone loss despite joint inflammation, showing normalized bone resorption and osteoclast formation.
  • Absence of IL1 completely reversed TNF-induced bone loss and RANKL elevation.

Conclusions:

  • IL1 is indispensable for TNF-mediated systemic bone loss.
  • IL1 acts as a critical mediator of inflammatory osteopenia, independent of joint inflammation.
  • Targeting IL1 may offer a therapeutic strategy for preventing bone loss in inflammatory conditions.